These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 13848447)

  • 1. Heparin resistance, measured by the plasma heparin thrombin time, in patients on long-term anticoagulatn therapy with phenylindanedione following coronary occlusion.
    HOLGER-MADSEN T; SCHIOLER M
    Thromb Diath Haemorrh; 1960 Mar; 4():261-8. PubMed ID: 13848447
    [No Abstract]   [Full Text] [Related]  

  • 2. Heparin resistance determined by the heparin tolerance test in patients treated with phenylindanedione before, during, and after operation.
    GORMSEN J; HAXHOLDT BF
    Acta Chir Scand; 1961; 121():367-76. PubMed ID: 13707283
    [No Abstract]   [Full Text] [Related]  

  • 3. Heparin resistance in acute coronary occlusion measured by the plasma heparin thrombin time.
    HOLGER-MADSEN T
    Acta Haematol; 1960 Apr; 23():195-207. PubMed ID: 14402593
    [No Abstract]   [Full Text] [Related]  

  • 4. [Phenylindanedione in the treatment of coronary artery disease. A study of its prolonged use in ambulatory patients].
    TANDOWSKY RM
    Sem Med; 1960 Nov; 117():1697-9. PubMed ID: 13775173
    [No Abstract]   [Full Text] [Related]  

  • 5. On the effect of heparin at various concentrations with particular reference to increased heparin resistance measured by the plasma heparin thrombin time.
    HOLGER-MADSEN T
    Thromb Diath Haemorrh; 1961 Dec; 6():573-9. PubMed ID: 13908340
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on increased heparin resistance measured by the plasma heparin thrombin time.
    HOLGER-MADSEN T
    Thromb Diath Haemorrh; 1961 Jul; 6():125-43. PubMed ID: 13715261
    [No Abstract]   [Full Text] [Related]  

  • 7. Phenylindanedione; a deserving anticoagulant.
    HARPER BF; JOHNSON R
    J Med Assoc Ga; 1956 Apr; 45(4):149-50. PubMed ID: 13307153
    [No Abstract]   [Full Text] [Related]  

  • 8. The plasma heparin thrombin time.
    HOLGER-MADSEN T
    Acta Haematol; 1959 May; 21(5):301-10. PubMed ID: 13660750
    [No Abstract]   [Full Text] [Related]  

  • 9. Histidine-rich glycoprotein modulates the anticoagulant activity of heparin in human plasma.
    Lijnen HR; Van Hoef B; Collen D
    Thromb Haemost; 1984 Apr; 51(2):266-8. PubMed ID: 6740558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin resistance (measured by the heparin thrombin time) and plasma fibrinogen in various diseases.
    HOLGER-MADSEN T; SCHIOLER M
    Acta Haematol; 1962; 27():294-305. PubMed ID: 13908339
    [No Abstract]   [Full Text] [Related]  

  • 11. [Thrombin time of heparin treated plasma; action of fibrinoplastic substances].
    BURSTEIN M; GUINAND A
    Rev Hematol; 1955; 10(3):567-70. PubMed ID: 13311030
    [No Abstract]   [Full Text] [Related]  

  • 12. Coexistence of hypofibrinogenaemia and thrombosis.
    GORMSEN J
    Acta Chir Scand; 1961; 121():367-76. PubMed ID: 13707288
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical experience with phenylindanedione].
    SLOER M; BEREZOVSKY M; BERSTEIN S; GNIECKO O; GUIMPEL A
    Dia Med; 1961 Oct; 33():2278-86. PubMed ID: 13913906
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anticoagulant therapy with phenylindanedione. A clinical analysis of 101 cases].
    BUZZI A; FUSTINONI O; CARBAJAL B
    Prensa Med Argent; 1959 Mar; 46():687-92. PubMed ID: 13806585
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative study on the antithrombotic effects of a synthetic thrombin inhibitor and of heparin in animal models.
    Hauptmann J; Barth A; Schönberger FP; Markwardt F
    Biomed Biochim Acta; 1983; 42(7-8):959-65. PubMed ID: 6651812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic trial of phenylindanedione ("pindione") in suppository form in hemorrhoids].
    MILSTEIN MJ
    Concours Med; 1960 Mar; 82():1509-12. PubMed ID: 14422695
    [No Abstract]   [Full Text] [Related]  

  • 17. Coagulation protein function: the influence of acetaldehyde-modified heparin on thrombin activity.
    Brecher AS; Fu Q
    J Investig Med; 1999 Jan; 47(1):76-80. PubMed ID: 10071484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the plasma thrombin time to assess the adequacy of in vivo neutralization of heparin: comparative studies following operations employing extracorporeal circulation.
    PEDEN JC; McFARLAND JA
    Blood; 1959 Nov; 14():1230-6. PubMed ID: 14431320
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antithrombin activity and prolongation of thrombin time; comparative study of heparin and of some synthetic heparinoids].
    BURSTEIN M; GUINAND A
    Arch Int Pharmacodyn Ther; 1955 Jun; 102(1-2):96-104. PubMed ID: 13239250
    [No Abstract]   [Full Text] [Related]  

  • 20. [Thrombin-antithrombin III complexes as a measure of effective heparin treatment?].
    Meyer D; Tsakiris DA; Marbet GA
    Schweiz Med Wochenschr; 1989 Sep; 119(39):1352-4. PubMed ID: 2678451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.